Market: Copenhagen Symbol: CHR ISIN: DK0060227585 Industry: Health Care
Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed.

Share Data 19/02/2020
Currency DKK
Previous Close 556.20
52 Weeks % -16.16
Volume 330,664
Number of Shares 131,852,496
Market Cap (bil.) 73.3
Previous Close Currency 52 Weeks % Volume Number of Shares Market Cap (bil.)
556.20 DKK -16.16 330,664 131,852,496 73.3

Key figures, EUR million
         
Income statement 2018/19 2017/18 2016/17 2015/16
Revenue 1,161.1 1,097.4 1,062.5 948.9
Gross profit 650.0 600.6 578.1 505.4
EBITDA before special items 407.8 384.0 368.1 324.0
EBIT before special items 343.2 320.2 307.1 267.8
EBIT 340.9 320.2 305.7 255.6
Net financial items (16.1) (24.1) (14.8) (16.2)
Profit for the year 250.2 228.2 224.0 183.8
Average number of employees (FTEs) 3,420 3,151 2,940 2,708
         
Financial position at August 31 2018/19 2017/18 2016/17 2015/16
Total assets 2,057.8 1,861.1 1,802.1 1,715.3
Invested capital 1,745.4 1,631.5 1,581.1 1,445.0
Net working capital 220.6 189.1 174.8 147.4
Equity 797.2 771.6 768.5 730.3
Net interest-bearing debt 734.4 658.7 628.4 547.9
         
Cash flow and investments 2018/19 2017/18 2016/17 2015/16
Cash flow from operating activities 298.6 302.4 283.7 244.8
Cash flow used for investing activities (81.6) (107.0) (176.5) (244.4)
Free cash flow 217.0 195.4 107.2 0.4
Free cash flow before acquisitions and special items 229.1 195.9 187.8 175.2
         
Earnings per share 2018/19 2017/18 2016/17 2015/16
EPS, diluted 1.90 1.73 1.68 1.40
         
Key ratios 2018/19 2017/18 2016/17 2015/16
Organic growth, % 7 9 10 12
Gross margin, % 56.0 54.7 54.4 53.3
EBITDA margin before special items, % 35.1 35.0 34.6 34.1
EBIT margin before special items, % 29.6 29.2 28.9 28.2
EBIT margin, % 29.4 29.2 28.8 26.9
ROIC, % 20.3 19.9 20.3 19.9
ROIC excl. goodwill, % 37.3 38.0 40.1 39.7
NWC, % 19.0 17.2 16.5 15.5
R&D, % 7.3 7.3 7.0 7.1
Capital expenditure, % 12.0 9.8 10.0 8.2
Net debt to EBITDA before special items 1.8x 1.7x 1.7x 1.7x